MabVax Therapeutics Files IND for Phase I Clinical Trial with HuMab 5B1 as a...
Enrollment Expected to Begin in Early 2016
View ArticleMabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in...
Patient Enrollment in Phase I Trial Expected to Begin in Early 2016
View ArticleMabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1
Enrollment in Trial with New PET Imaging Agent Expected to Begin in Early 2016
View ArticleMabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial...
Phase I Trials with HuMab-5B1 as Imaging Agent and Therapeutic Treatment Expected to Begin in the First Quarter of 2016
View ArticleMabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of...
HuMab-5B1 is a Fully Human Antibody With Remarkable Preclinical Specificity and Antitumor Activity Against Pancreatic Cancer
View Article
More Pages to Explore .....